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The characteristics and health needs of pregnant
women with schizophrenia compared with bipolar
disorder and affective psychoses
Clare L Taylor1*, Robert Stewart2, Jack Ogden1, Matthew Broadbent3, Dharmintra Pasupathy4 and Louise M Howard1
Abstract
Background: Most women with psychotic disorders and bipolar disorders have children but their pregnancies
are at risk of adverse psychiatric and fetal outcome. The extent of modifiable risk factors – both clinical and
socio-demographic – is unclear as most studies have used administrative data or recruited from specialist
tertiary referral clinics. We therefore aimed to investigate the socio-demographic and clinical characteristics of an
epidemiologically representative cohort of pregnant women with affective and non-affective severe mental illness.
Methods: Women with severe mental illness were identified from a large electronic mental health case register
in south London, and a data linkage with national maternity Hospital Episode Statistics identified pregnancies in
2007–2011. Data were extracted using structured fields, text searching and natural language processing
applications.
Results: Of 456 pregnant women identified, 236 (51.7%) had schizophrenia and related disorders, 220 (48.3%) had
affective psychosis or bipolar disorder. Women with schizophrenia and related disorders were younger, less likely
to have a partner in pregnancy, more likely to be black, to smoke or misuse substances and had significantly more
time in the two years before pregnancy in acute care (inpatient or intensive home treatment) compared with women
with affective disorders. Both groups had high levels of domestic abuse in pregnancy (recorded in 18.9%), were from
relatively deprived backgrounds and had impaired functioning measured by the Health of the Nation Outcome Scale.
Women in the affective group were more likely to stop medication in the first trimester (39% versus 25%) whereas
women with non-affective psychoses were more likely to switch medication.
Conclusions: A significant proportion of women, particularly those with non-affective psychoses, have modifiable risk
factors requiring tailored care to optimize pregnancy outcomes. Mental health professionals need to be mindful of the
possibility of pregnancy in women of childbearing age and prescribe and address modifiable risk factors accordingly.
Keywords: Schizophrenia, Bipolar disorder, Pregnancy
Background
Most women with severe mental illnesses (SMI; i.e.
schizophrenia and related delusional disorders, and bi-
polar disorder and affective psychoses) have children [1],
and with the use of newer antipsychotic medications
that do not raise prolactin, fertility in women with SMI
is increasing [2,3]. However SMI, whether affective or
non-affective, is associated with a range of adverse
consequences in pregnancy and the postpartum period.
Firstly acute psychiatric relapse may occur - inter-
nationally, the Confidential Enquiries into Maternal
Deaths highlight psychiatric illness as a leading contribu-
tor to maternal deaths [4,5] - and postpartum relapse
may also affect capacity to parent the infant [6]. Preg-
nancy is associated with discontinuation of psychotropic
medication in women with severe affective disorders
[7-9] but there is little known about rates and reasons
for discontinuation in women with schizophrenia.
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There is also increasing evidence that adverse fetal
outcomes, including small for gestational age babies,
prematurity and stillbirth, are associated with SMI
[10-13], and that these outcomes are at least partly due
to risk factors associated with SMI including socio-
demographic factors [1], smoking and substance misuse
[10], nutritional deficiencies [14], obesity [15] and do-
mestic violence [16]. However the prevalence of these
modifiable risk factors in these women is unclear as
most studies have used clinical data from specialist ser-
vices with limited generalizability, or have small clinical
samples with limited statistical power to investigate dif-
ferences between the groups [17], or have used adminis-
trative data of population cohorts with little detail on
clinical characteristics. It is also not clear to what extent
these risk factors differ in pregnant women with schizo-
phrenia and related delusional disorders compared with
women with bipolar disorder or affective psychoses.
We therefore aimed to establish a more representative
cohort of pregnant women with SMI, using detailed
electronic clinical health records. This would enable us
to investigate the prevalence of socio-demographic and
clinical risk factors, and establish whether these differ
in women with affective and non-affective SMI, in order
to inform service providers of this population’s health
needs. Given that schizophrenia is associated with poorer
physical and psychosocial functioning than affective
psychosis, we hypothesised that, compared with preg-
nant women with non-affective SMI, pregnant women
with affective SMI would have fewer behavioural risk
factors associated with adverse pregnancy outcomes
(e.g. smoking, domestic violence, substance misuse),
have better social support, fewer episodes of acute care
prior to pregnancy and be less likely to stop or switch
medication during pregnancy.
Methods
Data Source
The South London and Maudsley (SLaM) NIHR Bio-
medical Research Centre Clinical Record Interactive
Search (CRIS) system is a ‘new generation’ of case register
design, built on fully electronic clinical records (main-
tained since 2006), preserving anonymity through
technical and procedural safeguards [18]. SLaM pro-
vides near-monopoly mental healthcare for 1.2 million
people, as well as specialist services. CRIS, described in
detail elsewhere [19], allows searching and retrieval of
anonymised full records from SLaM including copies of
text fields (e.g. case notes, correspondence) with mask-
ing of identifiers [18]. CRIS currently accesses data on
over 250,000 individuals. Data can be extracted from
structured fields, or search terms can be entered to
perform targeted searches of the notes and correspond-
ence. Several natural language processing applications
have been developed using General Architecture for
Text Engineering (GATE) software in collaboration
with Sheffield University Department of Computer Sci-
ence. These applications derive structured data from
free text fields, taking into account the linguistic con-
text. Applications have been developed and validated
against human raters [20]. CRIS was approved as a
source of secondary data for research by Oxfordshire
Research Ethics Committee C (08/H0606/71 + 5). In-
formation can only be reported where there are more
than five participants in a cell to maintain anonymity.
Using a trusted third party in full compliance with
UK Data Protection law, CRIS data have been linked
with Hospital Episode Statistics (HES) [21], which
provide national statistical data on all hospital care in
England, including hospital admissions, outpatient
appointments, Emergency Room attendances and ma-
ternity care.
Study design and population
A cohort of women who were pregnant whilst receiving
SLaM care at any point from 2007–2011 inclusive was
assembled using CRIS and HES. Women with SMI were
eligible if they have ever had the following ICD-10 [22]
diagnoses recorded on the CRIS database: F20, F22, F23,
F25, F28, F29 (schizophrenia and related disorders,
schizoaffective disorders and delusional disorders), F30,
F31 (mania and bipolar affective disorders), F32.3, F33.3
(psychotic depression), F53.1 (severe mental and behav-
ioural disorders associated with the puerperium – specif-
ically puerperal psychosis). The HES linkage was used to
identify incidences of pregnancy in these women during
the study period. All women with first episode psychosis
occurring after or during the index pregnancy were then
excluded.
Diagnosis at baseline was assigned by extracting the
closest SMI diagnosis to 9 months before the HES
episode using CRIS structured fields and GATE soft-
ware. Where no diagnoses were extracted, notes and
correspondence histories were searched. Dating of
pregnancy was carried out using gestational age at
birth extracted from HES maternity data and used
as our ‘gold standard’. Where this was unavailable,
manual text searches in CRIS were carried out for
expected delivery dates or other indicators using
search terms related to pregnancy and birth. For the
remaining pregnancies, we adapted a published and
validated algorithm for estimating gestational age at
birth in electronic health plan databases [8,23] - full
term pregnancies were assigned a 270-day gestational
length and preterm pregnancies 245 days; first trimes-
ter was identified as 0–89 days [23]. For the purposes
of the current analysis, we used the first index preg-
nancy occurring in the study period.
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Measures
Socio-demographic characteristics for index (first) pregnancy
We extracted ethnicity from structured fields and cate-
gorised codes into ‘Black African/Caribbean/other’, ‘White
British/other’ , and ‘Mixed, Asian or other’. Patient
addresses on CRIS have been linked to small-area-level
UK Census data (2007 projections from the 2001
Census) to provide indices of multiple deprivation [24];
the higher the score, the more severe the deprivation (in
the 2007 report, indices range from 0.37 to 85.46 [24]).
Manual searches were carried out to establish number
of other children prior to index pregnancy, partner
status, smoking, alcohol and drug use during pregnancy,
recorded history of maternal abuse in childhood and
whether the woman had been a victim of domestic
abuse before and during pregnancy (encompassing
physical, sexual, emotional and coercive abuse).
Clinical characteristics
Deliberate self-harm in the two years prior to pregnancy
was ascertained from manual review of notes and cor-
respondence. Number of days in acute mental health
care in the two years before pregnancy (defined as an
inpatient episode or under the care of intensive home
treatment teams i.e. care provided at home by teams that
are available everyday who can visit up to three times
per day [25]) were extracted from structured fields
(or manual review of clinical text fields for pre-2006
period), supplemented by HES data for other (non-
SLaM) mental health services. Spells of acute care were
constructed whereby a spell comprised of a period of
treatment in acute mental health care (inpatient or home
treatment) where there was at least 7 days between
admissions and discharges. Time since last major
episode was calculated as the time from the beginning of
the most recent ‘spell’ of acute care in the 2 years prior
to conception.
Baseline level of functioning recorded in the two years
before pregnancy was estimated by using the highest total
adjusted score from the Health of the Nation Outcome
Scale (HoNOS), a routinely collected 12 item measure in
UK mental health services of health and social functioning
of people with severe mental illness. Patients with SMI
typically have a score of around 10 indicating clinically sig-
nificant limitation in functioning; patients under acute
care typically have scores around 14 [26].
The GATE medication application was used to extract
structured indicators describing medication from the
free text for three months before pregnancy and the first
trimester of pregnancy. This was used to guide the re-
trieval of relevant clinical text fields containing medica-
tion information for in-depth manual examination.
Stops, starts and switches in regular medication(namely
antipsychotics, mood stabilisers and antidepressants)
were noted and the recorded reasons for these. Two re-
searchers carried out these manual reviews on randomly
split portions of the sample with consensus meetings to
resolve uncertainties. Two raters (CT, JO) cross-checked
5 cases each week until satisfactory reliability was ob-
tained and then a consecutive 22 cases (26 pregnancies)
were independently rated for reliability analyses
Statistical analysis
Analyses were carried out using STATA, version 12.
Women were stratified into two main diagnostic groups –
non-affective SMI, comprising those with baseline
diagnoses of schizophrenia, delusional disorders, acute
and transient psychoses, schizoaffective disorders,
other non-organic psychoses and psychosis NOS - and
affective SMI, including bipolar affective disorder &
manic episodes, psychotic depression and history of
postpartum psychosis. As the classification of schizoaf-
fective disorders varies depending on the classification
system used (DSM-IIIR,-IV and -V criteria for schizoaf-
fective disorder are closer to schizophrenia, whereas
ICD-10 criteria seem to allow the inclusion of a broader,
more heterogeneous group of patients into the diagnosis
[27]), and is still the subject of debate, analysis was re-
peated by including women with schizoaffective disorder
in the affective group as a sensitivity analysis.
Descriptive analyses investigated demographic charac-
teristics and psychiatric history for the whole sample
and separately for each of the two diagnostic groupings,
using chi2 tests for categorical data, t-tests for normally
distributed data and non-parametric Mann–Whitney tests
for other continuous data. For this analysis, cases with
missing smoking, alcohol, or substance use status (defined
as any use in pregnancy) and non-users were combined so
we compared only those who were identified as users in
pregnancy. Prevalence of medication use was recorded for
each trimester for medication groups and each individual
medication. Comparisons were made using chi2 tests and
chi2 tests for trend were used to examine trends in medi-
cation by year of pregnancy. Where women had more
than one pregnancy over the duration of the study the first
(index) pregnancy was used for this analysis. Inter-rater
reliabilities were assessed by calculating percent agree-
ment for identification of antipsychotics, antidepressants
and mood stabilisers.
Results
Socio-demographic and clinical characteristics
We identified 456 women with SMI with 539 pregnancies
during the study period 2007–2011 (Figure 1); 68 women
had more than one pregnancy in the study period. Using
diagnoses recorded closest to the beginning of the first
(index) pregnancy, there were 236 (51.7%) women with
schizophrenia and related disorders (including 31 with
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schizoaffective diagnoses), and 220 (48.3%) women with
affective SMI (165 bipolar affective disorder, 48 psychotic
depression, and 7 with a history of postpartum psychosis
only). Secondary diagnoses recorded included 24 women
(5.3%) with substance use disorders, 13 (2.9%) with anxiety
disorders including obsessive compulsive disorder and
post-traumatic stress disorder, 13 (2.9%) with personality
disorders, 5 (1.1%) with pervasive learning difficulties, and
6 (1.3%) with “other” diagnoses including depressive disor-
ders, epilepsy, eating disorders and conduct disorders.
There was no difference in the duration of CRIS re-
cords available between the two diagnostic groups:
median (range) durations were 817 (0–5006) and 834.5
(0–5500) days for non-affective and affective SMI re-
spectively (p = 0.419).
Women with non-affective SMI were significantly
more likely to be of Black African or other black ethnicity,
younger, current smokers and using illicit substances dur-
ing pregnancy, and had more acute admissions and more
time in acute care in the two years before pregnancy com-
pared with the affective group (Table 1).
Medication
Agreement between the two raters was 92% - 100%. Six
pregnancies had missing medication data in the first
trimester. Table 2 summarises medication exposures in
the three months prior to pregnancy, and in the first
trimester of pregnancy. The most common antipsychotic
exposure was olanzapine. Rates of polypharmacy were
similar in affective (44.8%) compared to non-affective
SMI (38.9%) (chi2(1) = 1.11, p = 0.291). Of the regular
medication prescribed (antipsychotics, mood stabilisers
and antidepressants), antipsychotics were the most com-
mon medication exposure and more common in the non-
affective than affective SMI group, both in the 3 months
before pregnancy (chi2(1) = 27.22, p < 0.001) and in the
first trimester of pregnancy (chi2(1) = 31.15, p < 0.001).
Fifteen percent of pregnancies were exposed to mood
stabilisers, with 50% discontinuation rates in the first
trimester. Mood stabilisers were more commonly pre-
scribed for affective SMI in the 3 months before preg-
nancy (chi2(1) = 27.98, p < 0.001) and during the first
trimester (chi2(1) = 27.51, p < 0.001). The most com-
monly prescribed mood stabiliser was sodium valproate
(7.6% of all index pregnancies in the first trimester).
Antidepressants were more commonly prescribed in the
affective than non-affective group in the 3 months be-
fore pregnancy (chi2(1) = 13.60, p < 0.001) and during
the first trimester (chi2(1) = 14.12, p < 0.001). The most
common antidepressants prescribed were citalopram/
Figure 1 Identification of women with serious mental illness.
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escitalopram, fluoxetine and sertraline, followed by
venlafaxine and mirtazapine.
A high proportion (40.4%) of women stopped or
switched medication in the first trimester of pregnancy,
particularly mood stabilisers (Table 3). Women with
affective SMI were more likely to stop medication in the
first trimester compared with women with non-affective
SMI (chi2(1) = 6.54, p = 0.011), while women with non-
affective SMI were more likely to switch medication in
the first trimester of pregnancy (chi2(1) = 5.47, p = 0.019).
There was no difference between the affective and
non-affective groups in the proportion of women who
Table 1 Clinical and demographic characteristics of pregnant women with severe mental illness
Whole sample
N = 456
Non-affective
psychosis, N = 236
Affective SMI,
N = 220
P*
Ethnicity
Black African & other Black 221 (48.5) 137 (58.1) 84 (38.2) <0.001
White British & other White 152 (33.3) 58 (24.6) 94 (42.7)
Asian/ Mixed/Other 83 (18.2) 41 (17.4) 42 (19.1)
Deprivation score, median (range)1 34.9 (3.8-77.2) 35.4 (3.8-77.2) 33.6 (6.8-9.7) 0.226
Maternal age at 1st index delivery, mean (SD), 31.8 (6.2) 30.9 (6.4) 32.9 (5.8) <0.001
Partner during 1st index pregnancy
Yes 299 (68.7) 143 (63.8) 156 (73.9) 0.023
No 136 (31.3) 81 (36.2) 55 (26.1)
Number of children at 1st index pregnancy
0 197 (44.7) 101 (43.0) 96 (46.6) 0.682
1 125 (28.3) 71 (30.2) 54 (26.2)
2 68 (15.4) 38 (16.2) 30 (14.6)
>/=3 51 (11.6) 25 (10.6) 26 (12.6)
Victim of child abuse 106 (23.3) 60 (25.4) 46 (20.9) 0.254
Victim of domestic abuse before pregnancy 159 (34.9) 83 (35.2) 76 (34.6) 0.889
Victim of domestic abuse in pregnancy 86 (18.9) 45 (19.1) 41 (18.6) 0.906
Smoking in pregnancy 79 (17.3) 51 (21.6) 28 (12.7) 0.012
Alcohol use in pregnancy 77 (16.9) 40 (17.0) 37 (16.8) 0.970
Substance use in pregnancy 61 (13.4) 39 (16.5) 22 (10.0) 0.041
Self-harm in 2 years before pregnancy 67 (14.7) 41 (17.4) 26 (11.8) 0.094
Number of days of acute care in 2 years before pregnancy,
0 262 (57.5) 121 (51.3) 141 (64.1) 0.021
1-33 67 (14.7) 38 (16.1) 29 (13.2)
34-79 63 (13.8) 42 (17.8) 21 (9.6)
83-537 64 (14.0) 35 (14.8) 29 (13.2)
Number of acute admissions in 2 years before pregnancy
0 262 (57.5) 121 (51.3) 141 (64.1) 0.025
1 127 (27.9) 78 (33.1) 49 (22.3)
2 38 (8.3) 23 (9.8) 15 (6.8)
>2 29 (6.4) 14 (5.9) 15 (6.8)
Time since last admission (years)
1 year 104 (53.6) 65 (56.5) 39 (49.4) 0.326
2 years 90 (46.4) 50 (43.5) 40 (50.6)
Highest HoNOS total adjusted score in 2 years before pregnancy,
median (range)2
12 (0–36) 12 (0–36) 12 (0–28) 0.768
1Deprivation score, whole sample, n = 427, non-affective group, n = 222, affective group, n = 205.
2adjusted HoNOS, whole sample, n = 244, non-affective group, n = 146, affective group, n = 98.
*p values are for comparison between the affective and non-affective group.
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either stopped or switched medication in the first
trimester of pregnancy (chi2(1) = 0.63, p = 0.426). In
terms of the reasons why the 98 women stopped medi-
cation in the first trimester, 78.6% were recorded as
stopping because of the “pregnancy”, 7.1% due to “side
effects of medication”, 5.1% were recorded as “non-
compliance”, and 5.1% as due to symptoms improving.
Eighty nine (90.8%) stopped abruptly and 9 (9.2%)
Table 2 Recorded psychotropic medication use before/during early pregnancy in women with severe mental illness
Medication 90 days pre pregnancy, N (%) 1st trimester, N (%)
Whole sample Non-affective Affective Whole sample Non-affective Affective
N = 450 N = 234 N = 216 N = 445 N = 232 N = 213
No regular medication 126 (28.0) 61 (26.1) 65 (30.1) 133 (29.9) 65 (28.0) 68 (31.9)
Antipsychotics 255 (56.7) 160 (68.4) 95 (44.0) 247 (55.5) 158 (68.1) 89 (41.8)
Olanzapine 98 (21.8) 52 (22.2) 46 (21.3) 97 (21.8) 53 (22.8) 44 (20.7)
Risperidone 56 (12.4) 37 (15.8) 19 (8.8) 52 (11.7) 36 (15.2) 16 (7.5)
Aripiprazole 45 (10.0) 40 (17.1) 5 (2.3) 39 (8.8) 34 (14.7) 5 (2.4)
Quetiapine 35 (7.8) 14 (6.0) 21 (9.7) 29 (6.5) 11 (4.7) 18 (8.5)
Haloperidol 16 (3.6) 8 (3.4) 8 (3.7) 23 (5.2) 17 (7.3) 6 (2.8)
Trifluoperazine 8 (1.8) 6 (2.6) <5 9 (2.0) 7 (3.0) <5
Chlorpromazine <5 <5 <5 7 (1.6) <5 <5
Flupenthixol 8 (1.8) 8 (3.4) 0 8 (1.8) 8 (3.5) 0
Other1 24 (5.3) 18 (7.7) 6 (2.8) 23 (5.2) 18 (7.8) 5 (2.4)
Mood stabilisers 82 (18.2) 21 (9.0) 61 (28.2) 74 (16.6) 18 (7.8) 56 (26.3)
Sodium Valproate 41 (9.1) 15 (6.4) 26 (12.0) 34 (7.6) 13 (5.6) 21 (9.9)
Lithium 24 (5.3) <5 22 (10.2) 21 (4.7) <5 20 (9.4)
Lamotrigine 11 (2.4) <5 8 (3.7) 12 (2.7) <5 9 (4.2)
Carbamazepine/Topimarate 9 (2.0) <5 6 (2.8) 9 (2.0) <5 6 (2.8)
Antidepressants 107 (23.8) 39 (16.7) 68 (31.5) 103 (23.2) 37 (16.0) 66 (31.0)
Citalopram/ Escitalopram 25 (5.6) 11 (4.7) 14 (6.5) 28 (6.3) 11 (4.7) 17 (8.0)
Fluoxetine 28 (6.2) 7 (3.0) 21 (9.7) 25 (5.6) 8 (3.5) 17 (8.0)
Sertraline 15 (3.3) 8 (3.4) 7 (3.2) 17 (3.8) 9 (3.9) 8 (3.8)
Venlafaxine 18 (4.0) 5 (2.1) 13 (6.0) 16 (3.6) 5 (2.2) 11 (5.2)
Mirtazepine 15 (3.3) <5 11 (5.1) 11 (2.5) <5 7 (3.3)
Other2 16 (3.6) 7 (3.0) 9 (4.2) 17 (3.8) 5 (2.2) 12 (5.6)
Polypharmacy*
2 agents 104 (23.1) 49 (20.9) 55 (25.5) 97 (21.8) 49 (21.1) 48 (22.5)
>2 agents 31 (6.9) 13 (5.6) 18 (8.3) 33 (7.4) 13 (5.6) 17 (8.0)
Anxiolytics3 40 (7.5) 34 (6.5)
Lorazepam 13 (2.9) 9 (3.9) 4 (1.9) 9 (2.0) 5 (2.2) <5
Diazepam 10 (2.2) <5 8 (3.7) 8 (1.8) <5 5 (2.4)
Other3 14 (3.1) 7 (3.0) 7 (3.2) 12 (2.7) <5 8 (3.8)
Sedatives 35 (7.8) 15 (6.4) 20 (9.3) 37 (8.3) 16 (6.9) 21 (9.9)
Promethazine 15 (3.3) 8 (3.4) 7 (3.2) 21 (4.7) 10 (4.3) 11 (5.2)
Zopiclone/zolpidem 23 (5.1) 9 (3.9) 14 (6.5) 24 (5.4) 9 (3.9) 15 (7.0)
Side effects medication
Procyclidine 18 (4.0) 10 (4.3) 8 (3.7) 14 (3.2) 9 (3.9) 5 (2.4)
1antipsychotic “other” includes: , clozapine (n = 5), amisulpride, clopixol, piportil, prochlorperazine, sulpride.
2antidepressant “other” includes: amitriptiline, dosulepin, dothiepin, duloxetine, imipramine, maprotiline, paroxetine, repoxetine, trancyclopromine, trazodone,
trimipramine, tryptophan, lofepramine, selegiline.
3anxiolytics “other” includes: clonazepam, midazolam, chlordiazepoxide.
*refers to any combination of antidepressants, mood stabilisers and antipsychotic.
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stopped gradually; where patients had decided them-
selves to stop medication they all stopped medication
abruptly (n = 56), whereas for those that stopped after
discussion with a clinician, 30(76.9%) stopped abruptly.
Thirty three women switched medication in the first
trimester with the commonest reasons being because of
“pregnancy” (63.6%) and “side effects” (12.2%).
Disaggregated by year of pregnancy, for the proportion
of women being prescribed antipsychotic medication over
time - 47.7% of 1st index pregnancies in 2007 had first
trimester exposure to antipsychotics, 52.8% of pregnancies
in 2008, 58.7% of pregnancies in 2009, 59.2% in 2010 and
60.0% in 2011 (Chi2(1) =3.35, p = 0.067). Regarding mood
stabilisers in the first trimester, 20.9% were exposed in
2007, 20.8% in 2008, 14.1% in 2009, 11.3% in 2010 and
14.4% in 2011 (Chi2(1) = 3.12, p = 0.078. For antidepres-
sant medication use during the study period - in 2007,
22.1% were exposed, 20.8% in 2008, 26.1% in 2009, 25.4%
in 2010, and 22.2% in 2011 (Chi2(1) =0.12, p = 0.734).
A sensitivity analysis where schizoaffective disorder
was classified with affective SMI did not result in mean-
ingful changes other than for self-harm which was sig-
nificantly more common in the affective SMI group
categorised in this way, and for the number of days in
acute care and number of admissions before pregnancy
where differences were no longer statistically significant
(Additional file 1: Table S4).
Discussion
Main findings
We identified a cohort of 456 women with SMI pregnant
from 2007–2011. In this cohort , women with non-affective
SMI had significantly higher levels of recent acute psychi-
atric morbidity, less social support (more likely to be sin-
gle), were younger and had a higher prevalence of smoking
and substance misuse during pregnancy compared with
women with affective SMI. This suggests that women with
non-affective SMI will need particularly high levels of
support to optimise both psychiatric and obstetric adverse
outcomes. Pregnant women in both diagnostic groups were
from relatively deprived backgrounds, had significantly im-
paired levels of functioning and had relatively high levels of
domestic violence in pregnancy recorded in the clinical rec-
ord. Statistics from the local area show smoking in preg-
nancy to be at about 4.4% in the local catchment area [28]
suggesting our cohort of women with SMI were more likely
to smoke in pregnancy. However the prevalence in our
sample of women with SMI was much lower than the 38%
prevalence reported in a similar clinical population in a
retrospective case note review [17]; this is likely to reflect
under-reporting by patients and under-recording by clini-
cians. Some of these risk factors, notably smoking, sub-
stance misuse and domestic violence, are potentially
modifiable but, although there is evidence for the effect-
iveness of interventions such as smoking cessation pro-
grammes and domestic violence advocacy [29], these are
not currently tailored for women with SMI and more evi-
dence is needed on how to best support women with SMI
to reduce these risks. The data we have provided on
trauma (child abuse and domestic violence) are of particu-
lar significance as they could impact on child protection
outcomes and the need for trauma informed obstetric care.
Following the onset of pregnancy, a relatively high
proportion of women, around 40% in both diagnostic
Table 3 Regular medication changes in first trimester (n (%))
Whole sample Non-affective psychosis Affective SMI
Antipsychotics N = 247 N = 158 N = 89
Switched 28 (11.3) 21 (13.3) 7 (7.9)
Stopped 59 (24.0) 33 (21.9) 26 (29.2)
Stopped or switched 84 (34.0) 53 (33.5) 31 (34.8)
Mood stabilisers N = 74 N = 18 N = 56
Switched <5 0 <5
Stopped 36 (48.7) 9 (50.0) 27 (48.2)
Stopped or switched 37 (50.0) 9 (50.0) 28 (50.0)
Antidepressants N = 103 N = 37 N = 66
Switched <5 <5 <5
Stopped 27 (26.2) 7 (18.9) 20 (30.3)
Stopped or switched 30 (29.1) 9 (24.3) 21 (31.8)
Regular medication N = 312 N = 167 N = 145
Switched 32 (10.3) 23 (13.9) 9 (6.2)
Stopped 98 (31.4) 42 (25.2) 56 (38.6)
Stopped or switched 125 (40.1) 63 (37.7) 62 (42.8)
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groups, either stopped or switched medication in the
first trimester of pregnancy, particularly mood stabili-
sers. Women in the affective group were more likely
than women in the non-affective group to stop medica-
tion in the first trimester, but less likely to switch medi-
cation. Similar levels of changes in antipsychotic use
have been described in data from USA health plans [8]
and women in contact with a German teratology service
[30]. Around fifteen percent of pregnancies in this study
involved exposure to mood stabilisers, mainly sodium
valproate and lithium, with 50% discontinuation rates in
the first trimester; similar discontinuation rates have
been described in the USA [8] and in UK primary care
[31]. Our data on the extent of medication exposure in
early pregnancy therefore appears to be consistent with
other international studies and reflects concerns by both
clinicians and patients of teratogenicity. As teratogenic
effects are most likely in the first few weeks of preg-
nancy, stopping mood stabilisers when women know
they are pregnant may be too late to prevent these
effects, although the impact on neurodevelopment con-
tinues for valproate exposure throughout pregnancy
[32], so discontinuation would still be indicated. Never-
theless, as pregnancy is unplanned in 50-70% of preg-
nancies in women with SMI it may be safer not to
prescribe valproate to women of childbearing age other
than when other medication options have failed – and
NICE and SIGN guidelines do indeed recommend this
avoidance [33,34]. NICE 2007 guidelines also recommend
considering an antipsychotic as an alternative. This ap-
pears to be reflected in clinical practice here as there were
increases in antipsychotic exposures and decreases in
mood stabilisers in the changes in exposure to medication
during pregnancy over time from 2007–2011.
The impact of switching and discontinuation of medi-
cation is not clear as the limited literature to date has
been based on selected clinical samples of pregnant
women with bipolar disorder in whom discontinuation
of mood stabilisers was associated with a marked in-
creased risk of relapse during pregnancy after adjusting
for potential confounders [9]. Outside of the perinatal
period switching antipsychotics in people with bipolar
disorder [35] or schizophrenia [36,37] appears to be well
tolerated but discontinuation is associated with increased
risk of relapse, particularly where discontinuation is
carried out abruptly [9,38]. Women may be unaware that
most psychotropic medication prescribed is associated
with very small absolute risks in pregnancy while discon-
tinuation, particularly abrupt discontinuation, may lead to
relapse. Follow up of this cohort of women will enable us
to investigate the extent to which discontinuation or
switching of medication is associated with relapse in both
women with affective or non-affective psychoses but this
data suggests that psycho-education on the risks of abrupt
discontinuation in pregnancy is needed. We will also be
able to investigate obstetric outcomes.
Given that most women with SMI have children, and
fertility rates have been shown to be increasing [1-3],
our findings imply that more attention should be paid to
reproductive health when prescribing medications for
SMI in women of child bearing age. A high proportion
of women changed medication once pregnant. It is note-
worthy that in women taking the same medications for
epilepsy, far lower rates of discontinuation occur [31],
suggesting different attitudes to risk and benefit, despite
the fact that maternal deaths are more commonly asso-
ciated with mental disorders than epilepsy [4]. It is
therefore important for psychiatric services to imple-
ment recommendations for pre-conception counselling
for women with pre-existing chronic conditions so that
women can make better informed decisions about medi-
cation and support with other risk factors before con-
ception to optimise pregnancy outcomes.
Strengths and limitations
A major strength of this data is the size and likely gener-
alisability of the sample. The mental health provider
(South London and Maudsley NHS Foundation Trust)
provides near monopoly coverage of its geographical
area enabling us to have established a cohort of repre-
sentative women from an ethnically diverse population
with SMI in the perinatal period. However it includes
only women in receipt of secondary care, thus missing
cases managed exclusively in primary care. Although
these data come from the medical notes of patients in
one secondary mental health care provider and may thus
simply reflect the patterns of prescribing of clinicians in
a particular health care trust, the similar rates of medica-
tion discontinuation in pregnancy to other national and
international data suggests these data are more genera-
lizable to other areas and services.
In addition the CRIS database reflects a dynamic
cohort of women who may be referred in and out of
services and move from the catchment area; the use of
Hospital Episode Statistics, with full coverage of England,
allowed follow up for women who moved away or were
discharged and enabled us to collect data for women who
moved into the area.
Multiple statistical comparisons were made suggesting
some associations could have occurred by chance. How-
ever findings were in the expected direction suggesting
face validity and increasing evidence that our women are
a representative cohort of pregnant women with SMI.
The linkage to maternity data also provided a robust
method of identifying pregnancies including the whole
of England; however, maternity information has varying
levels of completeness, some systematic errors in its
transfer [39] and it does not include births taking place
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at home, which was 2.4% for England in 2011 [40]. Finally
by using the full clinical care records, a high level of
clinical detail can be collected. In particular we col-
lected more detailed data regarding medication use in
pregnancy than in many previous studies which have
used prescription registries and health plan data only.
However the quality of clinical data depends on the
accuracy and comprehensiveness of clinicians’ records
and some important data are missing such as Body
Mass Index and detailed descriptions of social support.
Conclusions
A range of potentially modifiable risk factors for adverse
outcomes of pregnancy and childbirth were identified
in this cohort of women with SMI, with women with
non-affective psychoses at particularly high risk. Health
providers should develop strategies for addressing these
risk factors, for example by discussing smoking cessa-
tion and referring to domestic violence advocacy before
and during pregnancy. However, research is still needed
to establish whether and how these interventions need
to be modified for this population. Optimisation of
medication similarly should ideally take place before
conception; prescribers of medication to women of
childbearing age need to be mindful of the possibility of
pregnancy and prescribe accordingly.
Additional file
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